Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cryoport: Detailed Update and Updated Projections Based on 3Q Results (CYRX, Buy, $10.35)

Key Points

Cryoport continued to show explosive growth in the third quarter as sales increased 76% to $5.3 million led…
Read more…

Cryoport: Updated Sales and Earnings Model (CYRX, Buy, $9.69)

Purpose of this Report

With the commercial launches of the CAR-T products Kymriah and Yescarta, I am expecting a significant upward…
Read more…

Cryoport: Gilead Update on Yescarta Strongly Supports My View That Cryoport has Explosive Sales Growth; An Important Upward Inflection is Approaching (CYRX, $8.75, Buy)

Investment Conclusions

Along with most investors interested in Cryoport, I am expecting and awaiting a sharp upward inflection in sales as…
Read more…

Cryoport: This Unique Company is Poised for Explosive Sales Growth; Price Weakness is a Buying Opportunity (CYRX, Buy, $6.68)

Investment Thesis

By my analysis, Cryoport and its stock are coiled like a spring for future strong performance. My model is…
Read more…

Cryoport: As Its Clients Transition from Clinical Development to Commercial, Growth Could Be Explosive (CYRX, $6.89, Buy)

Investment Perspective

Cryoport is in the very early stages of corporate development and has only minimal sales ($9.8 million on a…
Read more…

Cryoport: Upping 2020 Price Target from $14.50 to $20.00 (CYRX, Buy, $6.89)

Overview

Before reading this report, I would suggest reviewing my initriation report on Cryoport of April 12, 2017 ††and my update…
Read more…

My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)

Report Highlights

The pending approval of Novartisí Car-T drug tisagenlecleucel is the beginning of a new era of drugs based…
Read more…

Cryoport: Thoughts About FDA AdCom Meeting on Novartisís CAR-T Drug Tisagenlecleucel (CYRX, Buy, $4.86)

An FDA advisory committee will consider the BLA for Novartisís CAR-T product tisagenlecleucel tomorrow, July 12th for the treatment of…
Read more…

Cryoport: Initiating Coverage of this Highly Unique Health Care Company with a Buy (CYRX, Buy, $2.25)

Introduction

I am recommending purchase of Cryoport, which has developed a first mover, business model for providing cold chain logistics for…
Read more…